Waldenstrom Macroglobulinemia clinical trials at UCSD
2 research studies open to eligible people
Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
open to eligible people ages 18 years and up
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
La Jolla, California and other locations
Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
La Jolla, California and other locations
Last updated: